Ergonovine Pregnancy and Breastfeeding Warnings

Brand names: Ergotrate, Ergotrate Maleate

Ergonovine Pregnancy Warnings

Contraindicated

AU TGA pregnancy category: C

Comments:
-This drug should not be administered during pregnancy, during induction of labour, or during the first and second stage of labour prior to the delivery of the anterior shoulder.
-In breech presentation and other abnormal presentations, it should not be administered before delivery is complete.
-In multiple births it should not be administered before the last child has been delivered.

This drug has potent uterotonic activity. Uterine contraction may cause premature parturition or hypertonic labour. Tetanic contractions may result in decreased uterine blood flow and fetal distress. This drug should not be administered prior to delivery of the placenta. Administration prior to delivery of the placenta may cause captivation of the placenta or missed diagnosis of a second infant, due to excessive uterine contraction. There are no controlled data in human pregnancy.

AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

See references

Ergonovine Breastfeeding Warnings

Repeat doses are contraindicated

Excreted into human milk: Yes

Comments: A single dose should not prevent a mother from breastfeeding.

This drug is excreted in breast milk but in unknown amounts. This drug can inhibit prolactin secretion and in turn suppress lactation; it may produce ergotism in breast-fed infants. While a single dose should not prevent a mother from breastfeeding, this drug should be avoided in mothers who breastfeed.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer